B. Metzler Seel. Sohn & Co. Ag Ptc Therapeutics, Inc. Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $11.2 Billion
- Q3 2025
A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Ptc Therapeutics, Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 15,382 shares of PTCT stock, worth $1.16 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
15,382Holding current value
$1.16 Million% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding PTCT
# of Institutions
325Shares Held
83.2MCall Options Held
811KPut Options Held
207K-
Vanguard Group Inc Valley Forge, PA8.29MShares$624 Million0.01% of portfolio
-
Black Rock Inc. New York, NY7.77MShares$585 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.75MShares$583 Million6.35% of portfolio
-
Wellington Management Group LLP Boston, MA4.92MShares$370 Million0.06% of portfolio
-
Janus Henderson Group PLC London, X03.77MShares$284 Million0.11% of portfolio
About PTC THERAPEUTICS, INC.
- Ticker PTCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,541,000
- Market Cap $5.39B
- Description
- PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on...